Thrombolytic Agents: Nanocarriers in Controlled Release.

Blood Coagulation Delayed-Action Preparations / therapeutic use Fibrinolytic Agents / therapeutic use Humans Myocardial Infarction Thrombosis / drug therapy
drug delivery nanoparticles plasminogen activators thrombolytic agents thrombosis

Journal

Small (Weinheim an der Bergstrasse, Germany)
ISSN: 1613-6829
Titre abrégé: Small
Pays: Germany
ID NLM: 101235338

Informations de publication

Date de publication:
10 2020
Historique:
received: 12 03 2020
revised: 10 06 2020
pubmed: 14 8 2020
medline: 24 6 2021
entrez: 14 8 2020
Statut: ppublish

Résumé

Thrombosis is a life-threatening pathological condition in which blood clots form in blood vessels, obstructing or interfering with blood flow. Thrombolytic agents (TAs) are enzymes that can catalyze the conversion of plasminogen to plasmin to dissolve blood clots. The plasmin formed by TAs breaks down fibrin clots into soluble fibrin that finally dissolves thrombi. Several TAs have been developed to treat various thromboembolic diseases, such as pulmonary embolisms, acute myocardial infarction, deep vein thrombosis, and extensive coronary emboli. However, systemic TA administration can trigger non-specific activation that can increase the incidence of bleeding. Moreover, protein-based TAs are rapidly inactivated upon injection resulting in the need for large doses. To overcome these limitations, various types of nanocarriers have been introduced that enhance the pharmacokinetic effects by protecting the TA from the biological environment and targeting the release into coagulation. The nanocarriers show increasing half-life, reducing side effects, and improving overall TA efficacy. In this work, the recent advances in various types of TAs and nanocarriers are thoroughly reviewed. Various types of nanocarriers, including lipid-based, polymer-based, and metal-based nanoparticles are described, for the targeted delivery of TAs. This work also provides insights into issues related to the future of TA development and successful clinical translation.

Identifiants

DOI: 10.1002/smll.202001647 PMID: 32790000 PMC: PMC7702193
pubmed: 32790000
doi: 10.1002/smll.202001647
pmc: PMC7702193
mid: NIHMS1643950
doi:

Substances chimiques

Delayed-Action Preparations 0
Fibrinolytic Agents 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2001647

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL140951
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL137193
Pays : United States

Informations de copyright

© 2020 Wiley-VCH GmbH.

Références

Polymers (Basel). 2011 Sep 1;3(3):1377-1397
pubmed: 22577513
Science. 2012 Aug 10;337(6095):738-42
pubmed: 22767894
Expert Rev Mol Diagn. 2009 May;9(4):325-41
pubmed: 19435455
J Pharm Bioallied Sci. 2014 Jul;6(3):139-50
pubmed: 25035633
Adv Pharmacol. 1999;46:151-208
pubmed: 10332503
Ther Deliv. 2015;6(8):895-7
pubmed: 26271812
J Pharm Sci. 2007 Aug;96(8):2090-106
pubmed: 17286291
Int J Nanomedicine. 2012;7:5159-73
pubmed: 23055728
J Control Release. 2012 Sep 10;162(2):310-20
pubmed: 22800582
Eur J Immunol. 1990 Mar;20(3):493-9
pubmed: 2318247
J Nanosci Nanotechnol. 2011 Dec;11(12):11089-94
pubmed: 22409062
Thromb Res. 2003;111(4-5):243-9
pubmed: 14693171
J Biomed Mater Res A. 2007 Dec 1;83(3):806-12
pubmed: 17559117
Pharm Res. 2009 Mar;26(3):539-48
pubmed: 19034631
Circulation. 1993 Jun;87(6):1850-3
pubmed: 8504497
Int J Pharm. 2011 Jan 17;403(1-2):254-61
pubmed: 20971175
Expert Opin Drug Deliv. 2008 Nov;5(11):1185-98
pubmed: 18976130
J Am Chem Soc. 2007 Sep 19;129(37):11653-61
pubmed: 17718495
Angew Chem Int Ed Engl. 2006 May 5;45(19):3165-9
pubmed: 16572498
ACS Appl Mater Interfaces. 2018 Oct 31;10(43):36764-36775
pubmed: 30299938
Turk J Haematol. 2002 Jun 5;19(2):151-77
pubmed: 27264756
Biomaterials. 2008 Jan;29(2):228-37
pubmed: 17953984
J Drug Target. 2007 Feb;15(2):109-14
pubmed: 17365281
Thromb Haemost. 2005 Apr;93(4):627-30
pubmed: 15841305
Annu Rev Med. 1988;39:405-23
pubmed: 3130773
Nanomedicine (Lond). 2007 Aug;2(4):533-43
pubmed: 17716136
Arch Pharm Res. 2015 Oct;38(10):1822-9
pubmed: 25851624
Clin Cardiol. 1999 Mar;22(3):165-71
pubmed: 10084057
J Pharm Sci. 2011 May;100(5):1783-92
pubmed: 21374614
Biomacromolecules. 2017 Mar 13;18(3):865-876
pubmed: 28240872
Eur J Pharm Sci. 2013 Sep 27;50(1):93-101
pubmed: 23524253
Zhonghua Xin Xue Guan Bing Za Zhi. 2009 Nov;37(11):1035-8
pubmed: 20137334
Rev Cardiovasc Med. 2002;3 Suppl 2:S17-24
pubmed: 12556739
Eur J Pharm Biopharm. 2009 Aug;72(3):546-51
pubmed: 19362145
J Thromb Haemost. 2013 Aug;11(8):1565-73
pubmed: 23773778
J Drug Target. 2012 Apr;20(3):224-34
pubmed: 22087861
Mar Drugs. 2015 Aug 14;13(8):5156-86
pubmed: 26287217
Biomaterials. 2009 Oct;30(28):5125-30
pubmed: 19560812
J Cereb Blood Flow Metab. 2003 Aug;23(8):895-9
pubmed: 12902833
J Thromb Thrombolysis. 2013 Nov;36(4):458-68
pubmed: 23728739
J Biomed Mater Res A. 2019 Aug;107(8):1824-1831
pubmed: 31012233
Biotechnol Adv. 2004 Feb;22(4):287-307
pubmed: 14697452
Circulation. 1997 Jan 21;95(2):463-72
pubmed: 9008465
J Thromb Haemost. 2003 Jul;1(7):1343-8
pubmed: 12871267
Biomaterials. 2010 Dec;31(36):9499-510
pubmed: 20732712
Expert Opin Drug Deliv. 2018 Feb;15(2):173-184
pubmed: 28944694
Biochem Biophys Res Commun. 2019 Aug 20;516(2):565-570
pubmed: 31235258
Arterioscler Thromb Vasc Biol. 2011 Jun;31(6):1357-9
pubmed: 21441137
Clin Pharmacokinet. 2002;41(15):1229-45
pubmed: 12452736
Curr Interv Cardiol Rep. 2000 Aug;2(3):250-257
pubmed: 11096674
J Drug Target. 2018 Feb;26(2):95-109
pubmed: 28796540
Int J Pharm. 2015 Jul 5;488(1-2):127-35
pubmed: 25912230
Int J Stroke. 2018 Jan;13(1):57-65
pubmed: 28421878
Drugs. 1997;54 Suppl 3:11-6; discussion 16-7
pubmed: 9360848
Biomaterials. 2018 Feb;156:204-216
pubmed: 29216534
Int J Cardiol. 2016 Sep 15;219:282-4
pubmed: 27343421
Rev Cardiovasc Med. 2002;3 Suppl 2:S25-33
pubmed: 15112713
J Thromb Thrombolysis. 2010 Jul;30(1):29-35
pubmed: 20155435
Int J Hyperthermia. 2015 Feb;31(1):67-73
pubmed: 25766387
Expert Opin Investig Drugs. 2000 Nov;9(11):2689-94
pubmed: 11060830
Int J Nanomedicine. 2020 Mar 09;15:1549-1568
pubmed: 32210551
J Mater Chem B. 2020 Jan 28;8(4):787-793
pubmed: 31899460
J Thromb Thrombolysis. 2015 Aug;40(2):144-55
pubmed: 25829338
Biomed Microdevices. 2016 Jun;18(3):48
pubmed: 27206512
N Engl J Med. 1988 Oct 6;319(14):925-31
pubmed: 3138537
Ultrasound Med Biol. 2011 Nov;37(11):1828-37
pubmed: 21925787
Int J Nanomedicine. 2007;2(4):595-607
pubmed: 18203427
Vascul Pharmacol. 2006 Jan;44(1):1-9
pubmed: 16275118
Int J Pharm. 2012 Jan 17;422(1-2):179-84
pubmed: 22079712
Thromb Res. 2009 Jul;124(3):306-10
pubmed: 19217651
Colloids Surf B Biointerfaces. 2016 Jul 1;143:359-370
pubmed: 27022877
J Biol Chem. 1989 Oct 25;264(30):17947-52
pubmed: 2509450
J Control Release. 2014 Mar 10;177:42-50
pubmed: 24417965
J Biomed Mater Res A. 2012 Aug;100(8):2106-18
pubmed: 22615105
J Pharm Sci. 2011 Aug;100(8):3146-3159
pubmed: 21455978
Biomaterials. 2009 Oct;30(29):5751-6
pubmed: 19656559
Int J Nanomedicine. 2012;7:5137-49
pubmed: 23055726
Eur J Pharm Sci. 2011 Dec 18;44(5):589-94
pubmed: 22009110
Drugs. 1987 Jul;34(1):25-49
pubmed: 3308411
Thromb Haemost. 2018 Jan;118(1):42-53
pubmed: 29304524
J Biomed Nanotechnol. 2012 Aug;8(4):624-32
pubmed: 22852472
J Control Release. 2012 Jan 10;157(1):46-54
pubmed: 21930168
Thromb Res. 2007;119(6):777-84
pubmed: 16887172
J Pharm Sci. 2017 Dec;106(12):3623-3630
pubmed: 28826879
J Drug Target. 1995;3(4):301-10
pubmed: 8821004
Biomaterials. 2009 Jul;30(19):3343-51
pubmed: 19299010
Adv Drug Deliv Rev. 2008 Jun 30;60(10):1153-66
pubmed: 18486268
Theranostics. 2015 Jul 02;5(10):1098-114
pubmed: 26199648
Adv Funct Mater. 2016 Jun 14;26(22):3818-3836
pubmed: 27790080
J Cell Physiol. 2014 Dec;229(12):2142-52
pubmed: 24911927
J Thromb Thrombolysis. 2014 Jul;38(1):57-64
pubmed: 24671732
Biomaterials. 2017 Jun;128:94-108
pubmed: 28314136
Biopharm Drug Dispos. 1998 Jan;19(1):31-8
pubmed: 9510983
Ultrasound Med Biol. 2010 Jan;36(1):145-57
pubmed: 19900755
N Engl J Med. 1992 Jan 23;326(4):242-50
pubmed: 1727977
ACS Appl Mater Interfaces. 2014 Apr 23;6(8):5566-76
pubmed: 24693875
Int J Pharm. 2013 Apr 15;447(1-2):115-23
pubmed: 23454518
ACS Appl Mater Interfaces. 2018 Oct 3;10(39):32988-32997
pubmed: 30192506
Curr Pharm Des. 2015;21(30):4509-18
pubmed: 26295952
Am J Med. 2000 Jul;109(1):52-8
pubmed: 10936478
Yao Xue Xue Bao. 2003 Mar;38(3):231-5
pubmed: 12830724
Acta Biomater. 2018 Apr 1;70:227-236
pubmed: 29412186
Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3352-7
pubmed: 11248082
P T. 2010 Feb;35(2):95-105
pubmed: 20221326
IEEE Eng Med Biol Mag. 2009 Jan-Feb;28(1):12-22
pubmed: 19150767
Pharm Res. 2013 Jun;30(6):1663-76
pubmed: 23468049
J Control Release. 2008 Jun 24;128(3):224-32
pubmed: 18471921
Biotechnol Adv. 1996;14(3):239-66
pubmed: 14537155
Lancet. 1998 Oct 17;352(9136):1245-51
pubmed: 9788453
J Control Release. 2001 Jul 10;75(1-2):37-44
pubmed: 11451495
J Biomed Mater Res A. 2009 Dec;91(3):753-61
pubmed: 19051299
J Endovasc Ther. 2005 Apr;12(2):224-32
pubmed: 15823070
Thromb Haemost. 2003 Jul;90(1):64-70
pubmed: 12876627
Int J Pharm. 2016 Mar 30;501(1-2):300-10
pubmed: 26873394
Stroke. 2006 Feb;37(2):425-9
pubmed: 16373632
Nature. 1947 Jun 7;159(4049):779
pubmed: 20241608
J Control Release. 2010 Oct 15;147(2):269-77
pubmed: 20696194
Br J Exp Pathol. 1951 Dec;32(6):530-7
pubmed: 14895792
Eur J Pharm Biopharm. 2017 Apr;113:60-74
pubmed: 28012991
J Colloid Interface Sci. 2017 Sep 1;501:282-293
pubmed: 28460221
Int J Pharm. 2012 Mar 15;424(1-2):1-11
pubmed: 22222184

Auteurs

Soodabeh Hassanpour (S)

Department of Analytical Chemistry, Faculty of Science, Palacky University Olomouc, 17. Listopadu 12, Olomouc, 77146, Czech Republic.

Han-Jun Kim (HJ)

Department of Bioengineering, Center for Minimally Invasive Therapeutics (C-MIT) and California NanoSystems Institute University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Terasaki Institute for Biomedical Innovation, Los Angeles, CA, 90024, USA.
ORCID: 0000-0001-9238-7238

Arezoo Saadati (A)

Pharmaceutical Analysis Research Center, Tabriz University of Medical Sciences, Tabriz, 516614731, Iran.

Peyton Tebon (P)

Department of Bioengineering, Center for Minimally Invasive Therapeutics (C-MIT) and California NanoSystems Institute University of California-Los Angeles, Los Angeles, CA, 90095, USA.

Chengbin Xue (C)

Department of Bioengineering, Center for Minimally Invasive Therapeutics (C-MIT) and California NanoSystems Institute University of California-Los Angeles, Los Angeles, CA, 90095, USA.

Floor W van den Dolder (FW)

Department of Bioengineering, Center for Minimally Invasive Therapeutics (C-MIT) and California NanoSystems Institute University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Division Heart and Lungs, Department of Cardiothoracic Surgery, University Medical Center Utrecht, Utrecht, GA, 3508, The Netherlands.
Regenerative Medicine Center Utrecht, University Medical Center Utrecht, Utrecht, CT, 3584, The Netherlands.

Jai Thakor (J)

Department of Bioengineering, Center for Minimally Invasive Therapeutics (C-MIT) and California NanoSystems Institute University of California-Los Angeles, Los Angeles, CA, 90095, USA.

Behzad Baradaran (B)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, 516614731, Iran.

Jafar Mosafer (J)

Research Center of Advanced Technologies in Medicine, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, 9519633787, Iran.

Amir Baghbanzadeh (A)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, 516614731, Iran.

Natan Roberto de Barros (NR)

Department of Bioengineering, Center for Minimally Invasive Therapeutics (C-MIT) and California NanoSystems Institute University of California-Los Angeles, Los Angeles, CA, 90095, USA.

Mahmoud Hashemzaei (M)

Department of Pharmacodynamics and Toxicology, School of Pharmacy, Zabol University of Medical Sciences, Zabol, 9861618335, Iran.

Kang Ju Lee (KJ)

Department of Bioengineering, Center for Minimally Invasive Therapeutics (C-MIT) and California NanoSystems Institute University of California-Los Angeles, Los Angeles, CA, 90095, USA.

Junmin Lee (J)

Department of Bioengineering, Center for Minimally Invasive Therapeutics (C-MIT) and California NanoSystems Institute University of California-Los Angeles, Los Angeles, CA, 90095, USA.

Shiming Zhang (S)

Department of Bioengineering, Center for Minimally Invasive Therapeutics (C-MIT) and California NanoSystems Institute University of California-Los Angeles, Los Angeles, CA, 90095, USA.

Wujin Sun (W)

Department of Bioengineering, Center for Minimally Invasive Therapeutics (C-MIT) and California NanoSystems Institute University of California-Los Angeles, Los Angeles, CA, 90095, USA.

Hyun-Jong Cho (HJ)

Department of Bioengineering, Center for Minimally Invasive Therapeutics (C-MIT) and California NanoSystems Institute University of California-Los Angeles, Los Angeles, CA, 90095, USA.
College of Pharmacy, Kangwon National University, Chuncheon, Gangwon, 24341, Republic of Korea.

Samad Ahadian (S)

Department of Bioengineering, Center for Minimally Invasive Therapeutics (C-MIT) and California NanoSystems Institute University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Terasaki Institute for Biomedical Innovation, Los Angeles, CA, 90024, USA.

Nureddin Ashammakhi (N)

Department of Bioengineering, Center for Minimally Invasive Therapeutics (C-MIT) and California NanoSystems Institute University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Jonsson Comprehensive Cancer Center, Department of Radiology and Department of Chemical and Biomolecular Engineering, University of California-Los Angeles, Los Angeles, CA, 90095, USA.

Mehmet R Dokmeci (MR)

Department of Bioengineering, Center for Minimally Invasive Therapeutics (C-MIT) and California NanoSystems Institute University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Terasaki Institute for Biomedical Innovation, Los Angeles, CA, 90024, USA.
Jonsson Comprehensive Cancer Center, Department of Radiology and Department of Chemical and Biomolecular Engineering, University of California-Los Angeles, Los Angeles, CA, 90095, USA.

Ahad Mokhtarzadeh (A)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, 516614731, Iran.

Ali Khademhosseini (A)

Department of Bioengineering, Center for Minimally Invasive Therapeutics (C-MIT) and California NanoSystems Institute University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Terasaki Institute for Biomedical Innovation, Los Angeles, CA, 90024, USA.
Jonsson Comprehensive Cancer Center, Department of Radiology and Department of Chemical and Biomolecular Engineering, University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Department of Chemical and Biomolecular Engineering, Henry Samueli School of Engineering and Applied Sciences, University of California - Los Angeles, Los Angeles, CA, 90095, USA.
ORCID: 0000-0001-6322-8852

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

Recherchemedicale.com › Phénomènes physiologiques respiratoires et circulatoires › Phénomènes physiogiques du sang › Hémostase › Coagulation sanguine › Thrombolytic Agents: Nanocarriers in...
Recherchemedicale.com › Thérapeutique › Traitement médicamenteux › Systèmes de délivrance de médicaments › Préparations à action retardée › Thrombolytic Agents: Nanocarriers in...
Recherchemedicale.com › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents hématologiques › Fibrinolytiques › Thrombolytic Agents: Nanocarriers in...
Recherchemedicale.com › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Thrombolytic Agents: Nanocarriers in...
Recherchemedicale.com › États, signes et symptômes pathologiques › Processus pathologiques › Nécrose › Infarctus › Infarctus du myocarde › Thrombolytic Agents: Nanocarriers in...
Recherchemedicale.com › Maladies cardiovasculaires › Maladies vasculaires › Embolie et thrombose › Thrombose › Thrombolytic Agents: Nanocarriers in...